{
  "docId": "019de070-3a76-76eb-bdcd-70a194f2629a",
  "docSlug": "3b5651eafaa236908b5aaeea5fdc2dcc",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 28,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "The slide outlines a sequential cohort design for a clinical trial, moving from IV to SC administration.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-3a76-76eb-bdcd-70a194f2629a/22",
  "deckHref": "/decks/019de070-3a76-76eb-bdcd-70a194f2629a",
  "deckJsonHref": "/decks/019de070-3a76-76eb-bdcd-70a194f2629a.json",
  "deckAnchorHref": "/decks/019de070-3a76-76eb-bdcd-70a194f2629a#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.7,
        "x": 0.27,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Part 1 (IV) and Part 2 (SC) cohort progression from 1 to 5",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb776951-97e8-4dfb-8afd-bef38ad36dc9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.04,
        "y": 0.3
      },
      "kind": "list",
      "text": "Key Inclusion Criteria: Plasma tHcy >80 µm, ≥12 yrs of age. Endpoints: Safety and tolerability, PK, Reduction in plasma total homocysteine (tHcy) levels. Anticipate enrolling 16-20 pts. Weekly dosing for 4 weeks",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d56d2be-2f9c-42b0-9018-81452dec1a06",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.35,
        "x": 0.46,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "Phase 1/2 Trial Initiated in June 2020",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8985472a-f622-4dab-9e54-c34d1a6f9a65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "title",
      "text": "Dose dependent reduction in tHcy establishes proof of concept",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2fdf95c-1fe9-481c-b27f-5b174f278a04",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "ACN00177 for Homocystinuria – Phase 1/2 Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc6b94ec-0720-4a45-956e-f97a840338a7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "94ef7168-5b20-4c7a-8b83-9d23f187ddb6",
      "evidence": "Sequential cohort progression diagram",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}